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ABSTRACT 
 
Aims: Study on pharmacotherapeutic pattern on cardiovascular patients is rarely done. Patient’s 
demography, drug usage and its clinical outcome are the basis for the assessment of cardiac 
treatment. The aim of this study to analyze the demography of patients of ischemic heart disease 
along with drug usage and current trends of practice in Bangladesh.  
Methods: This study was carried out over a period of two months at different units of NICVD, 
situated at Dhaka, Bangladesh. A structured questionnaire was prepared to collect necessary data 
from patients. Descriptive statistics was used to represent the data.  
Results: A total 363 discharged patients were interviewed followed by the verification of their 
discharge report and other medical documents to obtain necessary information. Out of 363 
patients, frequency of male patients were high (74.66%, N= 271) than female patients (25.34%, 
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N=92). There is a trends of ischemic heart disease development after 40 years of age and found 
significant in this study (P< 0.05). In this study, 83.19% of total patients were above 40 years of 
age. We found a significant number of patients also had diabetes, asthma and chronic kidney 
disease. Treatment approach of ischemic heart disease includes pharmacotherapy, 
revascularization and percutaneous coronary intervention. 48 patients (13.22%) out of 363 went for 
revascularization and percutaneous coronary intervention was done to 25 patients (6.89%). The 
goal of Pharmacotherapy is to reduce blood cholesterol level, prevention of further platelet 
aggregation, reduction of angina and control of heart rate. In our study, we found that, statins, anti 
platelet and anti angina/anti ischemic drugs are core in the treatment of ischemic heart disease. 
Beta blocker, ACE inhibitor or ARB, CCB is commonly added to standard therapy to reduce 
mortality and for better therapeutic outcome. Among statins, the frequency of use of atorvastatin 
(87.93%), combination of clopidogrel and aspirin (73.90%) among anti platelet agents, combination 
of trimetazidine and nitroglycerine (61.56%) among anti angina/anti ischemic agents were highest. 
In our study, we found that bisoprolol was most commonly prescribed by the physicians among 
other beta blockers.  
Conclusion: The outcome of this study will be helpful for young professionals, general physicians 
and other professionals involved in the health care setting for the rational use of drugs and to 
formulate effective strategy for the management of ischemic heart disease.  
 
 
Keywords:  Ischemic heart disease; statins; anti-paltelet; NICVD; beta blocker; anti-anginal/anti 
ischemic. 
 
ABBREVIATIONS 
 
ACE :  Angiotensin Converting Enzyme 
ARB :  Angiotensin Receptor Blocker    
CABG :  Coronary Artery Bypass Graft  
CCB :  Calcium Channel Blocker 
CKD :  Chronic Kidney Disease 
DM :  Diabetes Mellitus 
IsHD :  Ischemic Heart Disease 
NICVD  : National Institute of Cardiovascular 
Disease 
PCI :  Percutaneous Coronary Intervention 
 
1. INTRODUCTION 
 
Cardiovascular diseases (CVD) may be defined 
as a group of disorders of heart and blood 
vessels categorized as coronary heart disease or 
ischemic heart disease (heart attack), 
cerebrovascular disease (stroke), disease of 
aorta and arteries including hypertension and 
peripheral arterial disease, congenital heart 
disease, rheumatic heart disease, 
cardiomyopathies and cardiac arrhythmias of 
varying patho-physiologic causes [1,2]. Stroke 
and heart attack are the acute events of 
cardiovascular disease featured by the blockage 
of blood flow to brain and heart. Strokes can be 
caused by bleeding from a blood vessel in the 
brain or by blood clots [1]. Cardiovascular 
disease is a global health burden and ranked one 
in terms of death worldwide. It is estimated that 
CVD’s cause for more than 17 millions death 
globally each year (30% of all deaths), 80% of 
which occur in low and middle income countries, 
which is expected that to rise more 38.9% by 
2030 [3]. Recently, there is a significant decrease 
in mortality due to CVD’s in UK, but CVD’s 
treatment costs a lot and holds second position 
in terms of mortality [4]. There is also a 
significant decrease of mortality due to 
cardiovascular diseases in recent years in USA 
and this remarkable decline has been fueled by 
rapid progress in both prevention and treatment, 
including precipitous declines in cigarette 
smoking, improvements in hypertension 
treatment and control, widespread use of statins 
to lower circulating cholesterol levels, and the 
development and timely use of thrombolysis and 
stents in acute coronary syndrome to limit or 
prevent infarction [5]. 
 
Bangladesh is lower middle income country 
having lots of challenges in its health sector. Now 
a day’s Bangladesh has been experiencing a 
epidemiological transition from communicable 
disease to non communicable disease and 
among all non communicable disease CVD;s 
ranked one in terms of death and disability [6,7]. 
Cardiovascular diseases associated with 
diabetes significantly increase the rate of 
complications and more difficult to manage. 
Bangladesh is a densely populated country and 
number of people suffering from cardiovascular 
disease is increasing day by day. If early 
prevention and long term rehabilitation program 
is not taken, will place a major burden in the 
health care system in Bangladesh and will leads 
 
 
 
 
Hasan et al.; BJMMR, 22(2): 1-9, 2017; Article no.BJMMR.34107 
 
 
 
3 
 
to disability of its people. The present study was 
undertaken to investigate the pharmacotherapy 
of ischemic heart disease patients along with the 
demography and associated co morbidity of 
discharged patients from a govt. based 
specialized cardiac hospital.    
 
2. METHODS 
 
This study was carried out over a period of two 
months among the patients discharged from 
different units of National Institute of 
Cardiovascular Diseases (NICVD), Dhaka, 
Bangladesh. Prior study, approval was taken 
from the authority to conduct this survey. This 
center serves as a referral center for patients 
requiring specialized cardio care and patients of 
all economic grades from all over the country 
come here to get proper treatment. A structured 
questionnaire was developed through different 
stages of cross check and analysis to collect 
data from the patients. Informed consent was 
taken from the patients that the information may 
be disseminated both nationally and 
internationally. A total 363 were enquired and 
their discharge prescriptions were verified to 
obtain other necessary information and 
pharmacotherapy. Patients who denied facing 
questionnaire and non cooperative were 
excluded from this study.  
 
3. RESULTS 
 
3.1 Demographic Characteristics of 
Patients 
 
Out of 363 patients discharged from different 
units of NICVD (Table 1), frequency of male 
(N=271, 74.66%) was higher than female (N=92, 
25.34%). In our study, we divide patients in 
different age group and our concern was to find 
out the highest prevalence of ischemia 
developed in any specific age group.  
 
The risk of development of ischemic heart 
disease increase with age and in this study we 
found that 83.19% percent of patients suffered 
from ischemic heart disease were above 40 
years of age and was statistically significant 
(P<0.05). According to this study, a total of 253 
patients out of 363 patients were from Dhaka 
division (69.7%), ranked one in terms of patients 
divisional distribution followed by Chittagong 
division (N=63, 17.36%). Distribution of patients 
from different division of Bangladesh is shown in 
Fig. 1. 
 
Table 1. Demographic characteristics of 
ischemic heart disease patients discharged 
from NICVD 
 
  No of  
patients  
(N) 
Percentage 
 (%) 
Sex 
Male 271 74.66 
Female 92 25.34 
Religion 
Islam 343 94.49 
Hinduism 20 5.51 
Age**     
<20 16 4.41 
20-30 12 3.31 
31-40 33 9.09 
41-50 106 29.2 
51-60 81 22.31 
61-70 84 23.14 
>70 31 8.54 
Distribution of patients of different division 
Dhaka 253 69.7 
Mymensingh 5 1.38 
Rajshahi 8 2.2 
Rangpur 5 1.38 
Khulna 15 4.13 
Barisal 9 2.48 
Sylhet 5 1.38 
Chittagong 63 17.36 
Comorbidity 
Only IsHD 232 63.91 
IsHD+DM 70 19.28 
IsHD+CKD 14 3.86 
IsHD+ DM 
+ CKD 
11 3.03 
IsHD+ Asthma 31 8.54 
IsHD+CKD 
+Asthma 
3 0.83 
IsHD+DM 
+Asthma 
2 0.55 
Cardiac intervention and surgery frequency  
Only  
pharmacotherapy 
290 79.89 
CABG 48 13.22 
PCI 25 6.89 
**Frequency of patients suffering from ischemic heart 
disease above 40 years of age were found significant 
statistically compared to the frequency of  patients of 
ischemic heart disease bellow 40 years of age             
(P<0.05). t-test of two unequal variance was done to 
find out the P value 
 
 
  
Fig. 1. Patient distribution from different division of Bangladesh
 
Our effort was also to find out associated 
complications with ischemic heart disease 
patients. Different diagnostic approaches were 
involved to find out the associated complications 
of patients when they were admitted in the 
hospital. After verifying all the reports physician 
confirmed their severity of disease and 
associated complications. According to this 
study, patients suffering from both ischemic heart 
 
 
Fig. 2. Approach of treatment of 
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disease and diabetes was highest (N=70, 
19.28%) (Table 1). Patients suffered from both 
ischemic heart disease with asthma holds the 
second position (N=31, 8.54%). In this study, we 
found that, 48 patients (13.22%) out of 363 
went for coronary artery bypass grafting and 
25 patients (6.89%) out of 363 went for 
percutaneous coronary intervention (Table
Fig. 2) 
ischemic heart disease patients 
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3.2 Pattern of Pharmacotherapy 
 
Pharmacotherapy was given to patients 
according to severity of disease and associated 
complications. Aim of this study was to 
investigate the pattern of pharmacotherapy and 
find the frequency of specific class of drug 
prescribed in the treatment of ischemic heart 
disease. During this study, we found that, all the 
prescription contained multiple medications. In 
this study, we found that, the use of anti             
platelet was highest in the treatment (No of 
prescription: 341, Prescription rate: 93.94%) 
followed by lipid lowering agent (No of 
prescription: 323, Prescription rate: 88.98%) and 
anti ischemic/anti anginal drug (No of 
prescription: 320, prescription frequency: 
88.15%), (Table 2). 
 
Most of the prescriptions contained combination 
drug product of a single therapeutic category and 
was observed in case of anti platelet, anti 
ischemic/anti angina and anti hypertensive 
agents (Table 3). In terms of use of anti platelet 
agents, frequency and prescription rate of 
combination of clopidogrel and aspirin was 
highest (No of prescription: 252, prescription 
rate: 73.90%). In terms of use of single anti 
platelet agent in a prescription, frequency of use 
of clopidogrel was most compared to single low 
dose of aspirin (No of prescription: 73 Vs 16, 
Prescription rate: 21.41 Vs 4.69). Patients 
suffering from ischemic heart disease required 
anti ischemic/anti angina drug therapy. 
Combination use of nitroglycerine and 
trimetazidine was highest (No of prescription: 
197, prescription rate: 61.56) compared to single 
use of either nitroglycerine (26.25%) or 
trimetazidine (12.19%). In our study, we found no 
combination use of lipid lowering agents. Use of 
atovastating was highest (No of prescription: 
284, Prescription rate: 87.83%) compared to 
other lipid lowering agents (Table 3). We found 
143 discharge order containing diuretic and 
among different diuretic combination use of 
frusemide and spironolactone was highest 
(86.71%) compared to single use of any other 
diuretic.  
 
4. DISCUSSION 
 
Investigation of clinical studies and pharmaco-
therapeutic pattern on cardiovascular patients is 
rarely done in our country and such type of study 
will allow in depth exploration of health problem 
associated with cardiovascular disease and 
better understanding of pharmacotherapy to 
young professionals to serve the patients.  This 
study was carried out in a govt. based 
specialized cardiac center for obvious reason.  
 
Number of male patients was higher compared to 
the female patients discharged from hospital. 
Generally, cardiovascular disease develops 7-10 
years later to men and is still the major cause of 
death in women. The risk of cardiovascular 
disease in women is often underestimated as 
there is a misperception that females are 
protected from heart disease. Level of self 
awareness regarding cardiovascular disease in 
women may be another factor and needs further 
investigation [8]. Cardiovascular disease usually 
develop in the late stage of life. In a review of 
global burden of cardiovascular disease, 
proportion of death was highest after 50 years of 
age and ranked one in terms of death compared 
to other chronic diseases [9]. In this study, we 
found the highest frequency of patients after 40 
years of age. Significant number of patients out 
from the Dhaka comes to this cardiac center to 
get their treatment. In our study, we found the 
patients load form Dhaka division was highest 
compared to other division. As, in every division 
of this country, medical college based hospital 
having all kinds of facility for the intensive 
treatment of cardiovascular disease is a reason 
for highest patient frequency from Dhaka division 
for treatment. Patients with diabetes are at 
increased risk of a wide range of complications 
and comorbidities, which adversely affect quality 
of life and mortality. Cardiovascular diseases, 
most commonly ischemic heart disease is the 
primary causes of morbidity and mortality among 
patients with diabetes. Uncontrolled glucose level 
leads micro and macrovascular complications 
which strongly related to development of 
ischemic heart disease and in long run affects 
major physiological system significantly increase 
the rate of suffering from, hyperlipidemia, stroke, 
retinopathy, nephropathy which will ultimately 
leads to multiple organ failure if there is no 
proper control over blood glucose level [10]. In 
this study, majority of our patients were suffering 
from ischemic heart disease only, but in terms of 
co-morbidity, patients of suffering from diabetes 
and ischemic heart disease was highest, 19.28% 
of total patients (Table 1). 
  
Treatment of ischemic heart disease involves 
pharmacotherapy, percutaneous coronary 
intervention or surgical revascularization, may be 
combination of them depending on patients
 
 
 
 
 
Hasan et al.; BJMMR, 22(2): 1-9, 2017; Article no.BJMMR.34107 
 
 
 
6 
 
Table 2. Prescription frequency and prescription rate of different therapeutic class 
 
Therapeutic class No of prescription Percent of (%) different groups of medicines  
Positive inotropic agent 49 13.50 
Diuretic 143 39.39 
ACE inhibitor 191 52.62 
Β blocker 280 77.13 
ARBs 45 12.40 
CCB 4 1.10 
Anti platelet 341 93.94 
Anti ischemic/Anti anginal 320 88.15 
Lipid lowering agent 323 88.98 
 
Table 3. Prescription frequency and prescription rate of drugs from different therapeutic class 
 
Drugs No of prescription Percent of prescription (%) 
Positive inotropic agent 49   
Digoxin 49 100 
Diuretic 143   
Frusemide and spironolactone 124 86.71 
Frusemide 17 11.89 
Indapamide 2 1.40 
ACE inhibitor 191   
Ramipril 188 98.43 
Lisinopril 1 0.52 
Perindopril 2 1.05 
β blocker 280   
Bisoprolol 77 27.5 
Carvedilol 129 46.07 
Metoprolol 74 26.43 
ARBs 45   
Olmesartan 20 44.44 
Losartan 25 55.56 
CCB 4   
Amlodipine 2 50 
Diltiazem 2 50 
CCB with β blocker 7   
Amlodipin & Atenolol 7 100 
CCB with ARBs 3   
 Amlodioin & Valsartan 3 100 
Anti platelet 341   
Clopidogrel & Aspirin 252 73.90 
Clopidogrel 73 21.41 
Low dose aspirin 16 4.69 
Anti ischemic/Anti anginal 320   
Nitroglycerin & trimetazidine 197 61.56 
Nitroglycerin 84 26.25 
Trimetazidine 39 12.19 
Lipid lowering agent 323   
Atorvastatin 284 87.93 
Rosuvastatin 25 7.74 
Pitavastatin 10 3.10 
Fluvastatin 3 0.93 
Fenofibrate 1 0.31 
 
condition and intensity of disease [11]. In this 
study, we found that most our patients were 
treated by drug therapy only and asked them for 
follow up visit at specific time interval to monitor 
the pharmacotherapy for better health outcome. 
Only 13.22% (N=48) of total patient undergone 
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for revascularization successfully and discharged 
from hospital. Pharmacotherapy of ischemic 
heart disease involves drugs from different 
categories like, lipid lowering agent, anti platelet 
agent, anti angina/anti ischemic agent, β 
blockers, ACE inhibitor, angiotensin receptor 
blocker, calcium channel blocker, diuretic, 
positive ionotropic agent [11]. Platelet plays an 
essential role in the pathogenesis of ischemia in 
coronary circulation, platelet aggregates together 
to form thrombus leads blockage in coronary 
circulation. Anti platelet drug therapy therefore is 
obvious in the management of ischemic heart 
disease as a primary and secondary preventive 
measure to reduce mortality [12]. Low dose 
aspirin and clopidogrel are most widely used anti 
platelet agent in Bangladesh and in many cases, 
depending on the intensity of disease; 
combination of low dose aspirin and clopidogrel 
is used in the management of ischemia. Blood 
cholesterol level is an important risk factor for the 
development of ischemic heart disease. High 
level of blood cholesterol leads to development 
of atherosclerosis results restricted blood flow 
leads to less supply of oxygen to heart muscle 
resulting chest pain. High blood cholesterol level 
is also associated with the patients of diabetes 
and is one of the vital reasons that of high risk 
factor for the diabetes patients to develop 
ischemic heart disease. Other risk factor for high 
blood cholesterol includes life style and food 
habit [13,14]. Among of many lipid lowering 
agents, statins are commonly used to reduce of 
cardiovascular events and also in the treatment 
of dyslipidemia. There are many reports have 
demonstrated the efficacy of statins in patients 
with ischemic heart disease. The West of 
Scotland Coronary Prevention Study 
(WOSCOPS) demonstrated statin induced 
reduces of cardiovascular events and 
cardiovascular mortality in patients with high 
cholesterol level but without ischemic heart 
disease. In the Cholesterol and Recurrent Events 
(CARE) trial, the cardioprotective effects of 
statins were also demonstrated in patients with 
myocardial infarction and average cholesterol 
levels [15]. Among many statins employed, 
Atorvastatin in its various dose ranging from 10-
40mg had highest frequency of use. Beta 
blockers, ACE inhibitors, Angiotensin receptor 
blockers (ARBs), Calcium channel blockers are 
commonly employed as an antihypertensive 
agent, but in current practice have multiple 
functions in the management of cardiovascular 
patients. Depending on intensity of ischemic 
heart disease, combination these drugs are used 
for proper management except there is any 
contraindication for patients. The selective beta 
blockers like bisoprolol, atenonol administration 
to patients with coronary artery disease resulted 
in increased survival and improved quality of life 
patients and therefore they are a key group of 
drugs for their management. In a clinical trial of 
newly diagnosed coronary heart disease 
patients, treatment with beta blockers was 
associated with lower risk of cardiac events. The 
Meta analysis of several randomized clinical 
trials demonstrated that ACE inhibitors or ARBs 
added to standard pharmacotherapy in patients 
with ischemic heart disease and normal systolic 
function significantly reduces total mortality 
[16,17,18,19]. In our study, we found similarities 
towards the usage pattern of beta blocker and 
ACE inhibitors in the treatment of ischemic heart 
disease patients. In terms of usage frequency, 
the use of ARB and Calcium channel blocker are 
less than beta blocker and ACE inhibitor. 
Patients suffering from ischemic heart disease 
may be hypertensive and for proper 
management of hypertension, single and 
combination use of such agents are also 
required. In our study we found the combination 
use of Frusemide and spironolactone compared 
to single use of either agent or any other single 
diuretic. As such combination of diuretic does not 
cause electrolyte imbalance compared to single 
use of diuretic, preferred by most physicians. 
Diuretic treatment in combination with standard 
therapy of ischemic heart disease might brings 
positive outcome as diuretics reduces peripheral 
resistance ultimately reduces cardiac work load 
and prescribed to patients upon consideration of 
overall pathological condition [20].  
 
5. CONCLUSION 
 
This survey based study suggests that, statins, 
anti platelet and anti anginal/ischemic drugs are 
major cardiovascular drugs used in the treatment 
of ischemic heart disease. Addition of beta 
blockers, ACE inhibitors, ARBs, diuretics to 
standard therapy bring better therapeutic 
outcome and reduce ischemic mortality rate. 
Depending on the intensity of pathology, 
revascularization and PCI is done to patients. As 
the goal of ischemic therapy is to lower the blood 
cholesterol level, prevention of further platelet 
aggregation, control of hypertension in 
hypertensive ischemic patients, a combination of 
drugs from different pharmacological category is 
required. Along with pharmacotherapy and 
surgical intervention, cardiac rehabilitation and 
change in life style is essential for better 
therapeutic outcome. High blood cholesterol, 
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diabetes, hypertension associated with life style 
is major risk factors for the development of 
ischemic heart disease. Findings of this study are 
a current scenario of demography of patients of 
ischemic heart disease and trends of 
pharmacotherapy by the physicians at a 
specialized cardiac hospital.  As this study was 
done a specialized cardiac center, variation of 
treatment pattern may be found with other 
generalized hospital.  
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